Lukas K van Vugt
Overview
Explore the profile of Lukas K van Vugt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
7
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Vugt L, Tegzess E, van der Zwan M, Clahsen-van Groningen M, de Winter B, Vart P, et al.
Clin Transplant
. 2024 Dec;
38(12):e70046.
PMID: 39636744
Background: Alemtuzumab can be an alternative to rabbit anti-thymocyte globulin (rATG) to treat severe or glucocorticoid-resistant acute T cell-mediated kidney transplant rejection (TCMR). Yet, there are few reports in which...
2.
van Haren E, van Vugt L, Wijbenga N, van der Sijs H, Hellemons M
J Heart Lung Transplant
. 2024 Jul;
43(11):1864-1868.
PMID: 39009290
We present an exceptional case of a lung transplant recipient successfully treated by multiple courses of alemtuzumab for refractory acute cellular rejection (ACR). The patient experienced multiple episodes of ACR...
3.
van Vugt L, Hesselink D, de Winter B
Br J Clin Pharmacol
. 2024 Jun;
PMID: 38889884
Cytomegalovirus (CMV) infection frequently occurs after solid organ transplantation and is associated with an increased morbidity and mortality. Fortunately, the development of valganciclovir prophylaxis has lowered the incidence of CMV...
4.
van Vugt L, van der Zwan M, Clahsen-van Groningen M, van Agteren M, Hullegie-Peelen D, de Winter B, et al.
Transpl Int
. 2023 Nov;
36:11834.
PMID: 38020744
Alemtuzumab is used as lymphocyte-depleting therapy for severe or glucocorticoid-resistant kidney transplant rejection. However, the long-term efficacy and toxicity of alemtuzumab therapy are unclear. Therefore, all cases of alemtuzumab anti-rejection...
5.
van Vugt L, Schagen M, De Weerd A, Reinders M, de Winter B, Hesselink D
Expert Opin Investig Drugs
. 2022 Sep;
31(10):1087-1100.
PMID: 36175360
Introduction: Kidney transplant rejection remains an important clinical problem despite the development of effective immunosuppressive therapy. Two major types of rejection are recognized, T-cell-mediated rejection (TCMR) and antibody-mediated rejection (ABMR),...
6.
Hesselink D, Hullegie-Peelen D, van Vugt L
Pharmacogenomics
. 2022 Jun;
23(10):567-570.
PMID: 35763447
No abstract available.
7.
van Vugt L, Wagenaar E, van Etten R
Ned Tijdschr Geneeskd
. 2021 Apr;
165.
PMID: 33914430
Objective: To analyse the incidence, risk factors and avoidability of acute kidney injury in adult patients admitted to a Dutch hospital. Design: Retrospective cohort study. Method: We assessed all consecutive...